10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2011 | |||
STATEMENTS OF OPERATIONS | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 21, 2012) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Revenues | |||
| Sanofi collaboration revenue | $ 326,609 | 311,332 | 247,140 |
| Other collaboration revenue | 43,072 | 75,393 | 67,317 |
| Net product sales | 44,686 | 25,254 | 18,364 |
| Technology licensing | 24,858 | 40,150 | 40,013 |
| Contract research and other | 6,599 | 6,945 | 6,434 |
| Total revenues | 445,824 | 459,074 | 379,268 |
| Expenses | |||
| Research and development | 529,506 | 489,252 | 398,762 |
| Selling, general, and admistrative | 117,261 | 65,201 | 52,923 |
| Cost of goods sold | 4,216 | 2,093 | 1,686 |
| Total expenses | 650,983 | 556,546 | 453,371 |
| Loss from operations | (205,159) | (97,472) | (74,103) |
| Other income (expense) | |||
| Investment income | 3,549 | 2,122 | 4,488 |
| Interest expense | (21,282) | (9,118) | (2,337) |
| Total other income (expense) | (17,733) | (6,996) | 2,151 |
| Net loss before income tax benefit | (222,892) | (104,468) | (71,952) |
| Income tax benefit | (1,132) | 0 | (4,122) |
| Net loss | (221,760) | (104,468) | (67,830) |
| Net loss per share, basic and diluted (in dollars per share) | (2.45) | (1.26) | (0.85) |
| Weighted average shares outstanding, basic and diluted (in shares) | 90,610 | 82,926 | 79,782 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2011 | |||
STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 21, 2012) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Cash flows from operating activities | |||
| Net loss | $ (221,760) | (104,468) | (67,830) |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities | |||
| Depreciation and amortization | 31,082 | 19,687 | 14,247 |
| Non-cash compensation expense | 56,094 | 39,897 | 31,259 |
| Other non-cash charges and expenses, net | 10,366 | 3,171 | 2,238 |
| Changes in assets and liabilities | |||
| Increase in Sanofi and trade accounts receivable | (21,118) | (17,518) | (30,494) |
| Increase in prepaid expenses and other assets | (6,033) | (7,303) | (4,436) |
| (Decrease) increase in deferred revenue | (40,329) | 158,151 | (27,497) |
| Increase in accounts payable, accrued expenses, and other liabilities | 50,016 | 7,605 | 12,577 |
| Total adjustments | 80,078 | 203,690 | (2,106) |
| Net cash (used in) provided by operating activities | (141,682) | 99,222 | (69,936) |
| Cash flows from investing activities | |||
| Purchases of marketable securities | (240,391) | (605,124) | (199,997) |
| Sales or maturities of marketable securities | 426,356 | 273,723 | 295,117 |
| (Increase) decrease in restricted cash and marketable securities | (277) | (5,941) | 50 |
| Capital expenditures | (57,217) | (99,689) | (97,318) |
| Net cash provided by (used in) investing activities | 128,471 | (437,031) | (2,148) |
| Cash flows from financing activities | |||
| Proceeds in connection with facility lease obligation | 0 | 47,544 | 23,640 |
| Payments in connection with facility lease obligation | (674) | (924) | (875) |
| Payments in connection with capital lease obligation | (993) | (104) | 0 |
| Proceeds in connection with issuance of convertible notes, net of debt issuance costs | 391,107 | 0 | 0 |
| Proceeds in connection with issuance of warrants | 93,800 | 0 | 0 |
| Payment in connection with purchase of convertible note hedges | (117,500) | 0 | 0 |
| Net proceeds in connection with issuance of Common Stock | 18,509 | 196,790 | 8,598 |
| Net cash provided by financing activities | 384,249 | 243,306 | 31,363 |
| Net increase (decrease) in cash and cash equivalents | 371,038 | (94,503) | (40,721) |
| Cash and cash equivalents at beginning of period | 112,572 | 207,075 | |
| Cash and cash equivalents at end of period | 483,610 | 112,572 | 207,075 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest | 14,725 | 12,737 | 2,525 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
REGENERON PHARMACEUTICALS, INC. | ||
Ticker: REGN Fiscal Year: 2011 | ||
BALANCE SHEETS | ||
Period Ending Dec 31, 2011 10-K (Filed: Feb 21, 2012) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2011 | Dec 31, 2010 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $ 483,610 | 112,572 |
| Marketable securities | 43,332 | 136,796 |
| Accounts receivable from Sanofi | 74,781 | 79,603 |
| Accounts receivable - trade, net | 28,254 | 2,314 |
| Prepaid expenses and other current assets | 22,898 | 26,337 |
| Total current assets | 652,875 | 357,622 |
| Restricted cash and marketable securities | 7,721 | 7,518 |
| Marketable securities | 275,887 | 370,053 |
| Property, plant, and equipment, at cost, net of accumulated depreciation and amortization | 367,955 | 347,450 |
| Other assets | 19,145 | 6,789 |
| Total assets | 1,323,583 | 1,089,432 |
| LIABILITIES and STOCKHOLDERS' EQUITY | ||
| Current liabilities | ||
| Accounts payable and accrued expenses | 95,625 | 53,658 |
| Deferred revenue from Sanofi, current portion | 20,011 | 19,506 |
| Deferred revenue - other, current portion | 31,629 | 35,217 |
| Facility lease obligations, current portion | 1,006 | 675 |
| Total current liabilities | 148,271 | 109,056 |
| Deferred revenue from Sanofi | 86,017 | 97,081 |
| Deferred revenue - other | 162,593 | 188,775 |
| Facility lease obligations | 159,508 | 159,355 |
| Convertible senior notes | 275,019 | 0 |
| Other long term liabilities | 6,443 | 7,350 |
| Total liabilities | 837,851 | 561,617 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity | ||
| Preferred stock | 0 | 0 |
| Common Stock | 91 | 87 |
| Additional paid-in capital | 1,754,824 | 1,575,780 |
| Accumulated deficit | (1,267,323) | (1,045,563) |
| Accumulated other comprehensive loss | (1,862) | (2,491) |
| Total stockholders' equity | 485,732 | 527,815 |
| Total liabilities and stockholders' equity | 1,323,583 | 1,089,432 |
| Class of Stock | ||
| Class A Stock | ||
| Common Stock | 2 | 2 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2011 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |